Table 5.
Proportion of molecular subtype of second primary breast cancer (SPBC)
| Sites of first primary cancer | With/Without Radiotherapy | P Value | With/Without Chemotherapy | P Value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||||
| Total | HR-/HER2-(%) | HR-/HER2+ (%) | HR+/HER2- (%) | HR+/HER2+ (%) | Total | HR-/HER2- (%) | HR-/HER2+ (%) | HR+/HER2- (%) | HR+/HER2+ (%) | |||
| Thyroid | 556/598 | 6.29/11.20 | 2.70/2.68 | 75.90/75.42 | 15.11/10.70 | 0.007 | 4/1150 | 0/8.87 | 25.00/2.61 | 50.00/75.74 | 25.00/12.78 | / |
| Melanoma of skin | 7/988 | 28.57/8.91 | 0/3.64 | 57.14/77.63 | 14.29/9.82 | / | 4/991 | 0/9.08 | 0/3.63 | 100/77.40 | 0/9.89 | / |
| Uteri | 565/1639 | 10.27/9.33 | 2.65/3.29 | 79.47/78.28 | 7.61/9.09 | 0.56 | 289/1915 | 12.46/9.14 | 2.08/3.29 | 77.51/78.75 | 7.96/8.83 | 0.227 |
| Urinary | 11/1038 | 18.18/8.96 | 0/3.85 | 72.73/77.94 | 9.09/9.25 | / | 78/971 | 6.41/9.27 | 2.56/3.91 | 80.77/77.65 | 10.26/9.17 | 0.733 |
| Colon/Rectum/Anus | 258/1576 | 8.91/8.76 | 1.55/3.93 | 77.91/79.76 | 11.63/7.55 | 0.053 | 582/1252 | 8.42/8.95 | 3.26/3.75 | 78.52/79.95 | 9.79/7.35 | 0.332 |
| Ovarian | 8/425 | 12.50/18.59 | 0/3.06 | 50.00/72.00 | 37.50/6.35 | / | 289/144 | 21.45/12.50 | 3.11/2.78 | 69.20/76.39 | 6.23/8.33 | 0.123 |
| Lymphoma/Leukemia | 184/910 | 9.78/10.77 | 4.89/3.41 | 73.91/77.03 | 11.41/8.79 | 0.494 | 551/543 | 11.07/10.13 | 3.27/4.05 | 76.59/72.74 | 9.07/9.39 | 0.829 |
| Oral/Pharynx | 142/151 | 9.86/13.91 | 8.45/1.99 | 76.06/76.82 | 5.63/7.28 | 0.063 | 65/228 | 7.69/13.16 | 10.77/3.51 | 75.38/76.75 | 6.15/6.58 | 0.122 |
| Lung/Bronchus | 190/551 | 14.74/11.43 | 6.32/3.81 | 70.00/77.31 | 2.29/7.44 | 0.199 | 213/528 | 16.90/10.42 | 5.63/3.98 | 69.95/77.65 | 7.51/7.95 | 0.061 |
Stratified by site of first primary cancer, radiotherapy and chemotherapy.